FindTrial
Sign In

Dihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in Sudan

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01075945
Enrollment
140
Registered
2010-02-25
Start date
2010-02-28
Completion date
2010-04-30
Last updated
2010-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malaria

Keywords

antimalarials, ACTs, Piperaquine, uncomplicated

Brief summary

Dihydroartemisinin- Piperaquine is not inferior to artemether-lumefantrine

Interventions

DRUGDihydroartemisinin- piperaquine

three tablets per day

DRUGartemether- lumefantrine

twenty tablet in eight doses

Sponsors

Southeast University, China
CollaboratorOTHER
University of Khartoum
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
5 Years to 95 Years
Healthy volunteers
No

Inclusion criteria

* Uncomplicated malaria

Exclusion criteria

* Severe cases * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
comparing the cure rate between the two drugs3 monthsPCR cure rate Parasite clearance time Fever clearance time

Countries

Sudan

Contacts

Primary ContactIshag Adam, MD, PhD
ishagadam@hotmail.com+249912168988
Backup ContactFatih M Malik, MD
ishagadamm@yahoo.com+249911259199

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026